Table 1. Patient and tumour characteristics.
| Cohort (n = 48) | |
|---|---|
| Age | |
| < 70 | 28 |
| ≥ 70 | 20 |
| Histopathology | |
| Typical carcinoid | 15 |
| Atypical carcinoid | 32 |
| Unknown* | 1 |
| Ki67 % | |
| < 3 | 15 |
| 3–20 | 31 |
| Unknown | 2 |
| Sites of disease** | |
| Liver | 37 |
| Bone | 36 |
| Lymph nodes | 29 |
| Lung | 13 |
| Subcutaneous | 3 |
| Pleura | 3 |
| Brain | 3 |
| Adrenal | 2 |
| Other (breast, gallbladder, ovary, thyroid) | 5 |
| Prior lines of systemic treatment | patients |
| 0 | 7 |
| 1 | 32 |
| 2 | 7 |
| ≥ 3 | 2 |
| Chromogranin A (x ULN^) | patients |
| < 2 | 15 |
| ≥ 2 | 30 |
| Unknown | 3 |
| Symptomatic | patients |
| Yes | 42 |
| Secretory symptoms | 30 |
| Non-secretory symptoms | 33 |
| No. of PRRT courses | patients |
| 1 | 42 |
| 2 | 4 |
| 3 | 2 |
| No. of PRRT doses per course | patients |
| ≤ 2 | 4 |
| 3 | 2 |
| 4 | 33 |
| 5 | 1 |
| 6 | 5 |
| ≥ 7 | 3 |
*no accessible histopathology(overseas sample). **multiple sites documented where applicable. ^ xULN = multiples of Upper Limit of Normal in local laboratory.